Part 1 sequential multi-gene sequencing (Simple NGS),
* Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations)
* And if no contributive:
Part 2: randomized study between two sequential approaches
\- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel)
1. MMR status in molecular biology
2. \- Tumour Mutational Burden
* Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary